Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00637390
Recruitment Status : Terminated (Genzyme will no longer supply the study drug for this trial as it does not believe the study will not fully enroll within an appropriate time frame.)
First Posted : March 18, 2008
Last Update Posted : December 2, 2016
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Brief Summary:
Ovarian cancer cannot grow without recruiting new blood vessels. Studies in humans have identified a novel cell population, termed vascular leukocytes (VLCs). While VLCs are not cancer cells, they support the growth of ovarian cancer cells by stimulating the growth of new blood vessels which provide the cancer with nutrients. VLCs make a protein termed CD52. An antibody therapeutic, Alemtuzumab (also know as Campath), that kills cells that make the CD52 protein has been successfully used to treat certain lymphomas (a type of blood cell cancer) that make CD52 protein. The purpose of this study is to determine if Alemtuzumab given subcutaneously (under the skin)can be safely given to patients with ovarian, fallopian, or primary peritoneal cancers to kill VLCs and determine if Alemtuzumab, by eliminating VLCs, can restrict tumor growth or increase response rates to chemotherapy given after the discontinuation of chemotherapy.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer Drug: Alemtuzumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
Study Start Date : March 2008
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Arm Intervention/treatment
Experimental: one Drug: Alemtuzumab
will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks

Primary Outcome Measures :
  1. safety & maximally tolerated dose [ Time Frame: Maybe 2 years ]

Secondary Outcome Measures :
  1. Effectiveness of Alemtuzumab to eliminate VLCs. [ Time Frame: Maybe 2 years ]
  2. Assess molecular markers associated with reduction in VLCs. [ Time Frame: Maybe 2 years ]
  3. Anti-tumor activity measured by decline or stabilization of CA125(a protein that is a tumor marker)or radiological(ie. CT, MRI, X-Ray)improvement or improvement in progression free survival. [ Time Frame: Maybe 2 years ]
  4. Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy. [ Time Frame: Maybe 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have a diagnosis of histologically confirmed ovarian, fallopian or primary peritoneal cancer that has progressed or recurred in the abdomen or pelvis after salvage chemotherapy as documented by either:

    1. Radiologic studies or
    2. Rising CA125 levels on two independent measurements. If the patient's CA125 has fallen into a normal range, CA125 relapse will be defined as double the nadir CA125. However, if the patients CA125 nadir had fallen to less than 10, then the measurements documenting recurrence or progression must be greater than 20.
  2. There is no limit on prior courses of chemotherapy.
  3. Patients must have unidimensional measurable disease or elevated CA125
  4. Age greater than 18 years.
  5. ECOG performance status less tha 2 (Karnofsky 60%).
  6. Life expectancy of greater than 12 weeks.
  7. Patients must have adequate organ and marrow function
  8. Ability to understand and the willingness to sign a written informed consent document. All patients must be informed of the investigational nature of this study and must sign an informed consent in accordance with institutional and federal guidelines.
  9. Timing guideline for pre-study labs and measurements:

All pre-study labs required for determination of eligibility are to be completed within 28 days of treatment Day 1.

X-rays and/or scans used for tumor measurement to determine disease status are to be completed within 28 days of treatment Day 1.

Women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

  1. Patients with known immunosuppressive diseases are excluded from this trial due to the known immunosuppressive nature of Alemtuzumab therapy.
  2. Patients may not be receiving any other agents (investigational or otherwise) with therapeutic intent.
  3. Patients with prior malignancy, except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease free for 2 years.
  4. Patients with a history of allergic reactions to Alemtuzumab or other humanized immunotherapeutics.
  5. Patients with unresolved bacterial, fungal, or viral infections requiring active treatment. Patients may be registered two weeks after the conclusion of antibiotic or anti-viral therapy.
  6. Patients with history of active CMV disease as Alemtuzumab therapy has been associated with CMV reactivation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00637390

Layout table for location information
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan Rogel Cancer Center

Layout table for additonal information
Responsible Party: University of Michigan Rogel Cancer Center Identifier: NCT00637390    
Other Study ID Numbers: UMCC 2007.120
First Posted: March 18, 2008    Key Record Dates
Last Update Posted: December 2, 2016
Last Verified: December 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Neoplasms by Site
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Fallopian Tube Diseases
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents